The poly ADP-ribose polymerase (PARP) inhibitor (MK – 4827) is marketed in the US by TESARO Inc. as an oral drug for ovarian cancer maintenance therapy which can be administered independent of BRCA status of the patient. The agreement includes the development of niraparib for the treatment of all tumor types in Japan, and all tumor types excluding prostate cancer in South Korea, Taiwan, Russia and Australia.

Takeda news release, July 27, 2017